Catalyst Dossier · compiled by CeliA 🧫

Arcus Biosciences, Inc. (RCUS)

Pharmaceutical Preparations · market cap $3.1B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Arcus Biosciences (RCUS) is a clinical-stage oncology company with a broad pipeline spanning Phase 2-3 assets across gastrointestinal, lung, renal, and prostate cancers. The company suffered two simultaneous Phase 3 failures on June 15, 2026, and carries only ~4.4 months of cash runway at current burn, making near-term financing a near-certainty. At a $3.9B market cap, the stock is pricing in considerable pipeline optionality despite a materially weakened balance sheet.

The catalyst path

2026-08-05Earningsimp 5/10
2026-12-31 (est.)Trial Startimp 3/10
2027-01-15 (est.)Phase 2 · Quemliclustatimp 7/10
2027-01-15 (est.)Phase 3 · Quemliclustatimp 9/10
2027-05-15 (est.)Phase 2 · Zimberelimabimp 7/10

Pipeline

Asset	Phase	Indication
Domvanalimab	Phase 3	Advanced Upper Gastrointestinal Tract Adenocarcinoma
AB680	Phase 2	Metastatic Colorectal Cancer
Casdatifan	Phase 3	Metastatic Clear Cell Renal Cell Carcinoma
Etrumadenant	Phase 2	Prostatic Neoplasms, Castration-Resistant
Quemliclustat	Phase 3	Gastrointestinal Tract Malignancies
Zimberelimab	Phase 3	Non Small Cell Lung Cancer
Nab-paclitaxel	Phase 3	Metastatic Pancreatic Ductal Adenocarcinoma

Price & technical context

3-month

+38.9%

6-month

+30.6%

12-month

+262.8%

52-wk range

$8.22–$31.08

vs 50-day MA

+19.4%

vs 200-day MA

+39.4%

Realized vol

62.2%

Max drawdown

-62.7%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RCUS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.